Bio Techne Corp Stock Analysis

Bio Stock Analysis Notes

About 100.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.83. Bio Techne Corp last dividend was issued on the 17th of November 2025. The entity had 4:1 split on the 30th of November 2022. Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. Bio-Techne operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3000 people. To find out more about Bio Techne Corp contact Charles Kummeth at 612 379 8854 or learn more at https://www.bio-techne.com.

Bio Techne Corp Investment Alerts

Bio Largest EPS Surprises

View All Earnings Estimates

Bio Techne Environmental, Social, and Governance (ESG) Scores

Bio Stock Institutional Investors

Note, although Bio Techne's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Bio Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 10.3 B.

Bio Profitablity

The company has Profit Margin (PM) of 0.06 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.17 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.17.

Management Efficiency

Bio Techne Corp has return on total asset (ROA) of 0.0625 % which means that it generated a profit of $0.0625 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.038 %, meaning that it created $0.038 on every $100 dollars invested by stockholders. Bio Techne's management efficiency ratios could be used to measure how well Bio Techne manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to 0.05. The current Return On Capital Employed is estimated to decrease to 0.05. As of now, Bio Techne's Other Current Assets are increasing as compared to previous years. The Bio Techne's current Total Current Assets is estimated to increase to about 734.5 M, while Other Assets are projected to decrease to under 8.8 M.

Technical Drivers

As of the 7th of February, Bio Techne shows the Risk Adjusted Performance of 0.0629, downside deviation of 1.86, and Mean Deviation of 1.77. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Bio Techne, as well as the relationship between them.

Bio Techne Corp Price Movement Analysis

Bio Techne Corp Insider Trading Activities

Bio Techne Outstanding Bonds

Bio Techne Predictive Daily Indicators

Bio Techne Corporate Filings

Bio Techne Forecast Models

Bio Techne's time-series forecasting models are one of many Bio Techne's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bio Techne's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Bio Techne Bond Ratings

Bio Techne Corp financial ratings play a critical role in determining how much Bio Techne have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Bio Techne's borrowing costs.

Bio Techne Corp Debt to Cash Allocation

Bio Techne Corp currently holds 444.06 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Bio Techne Corp has a current ratio of 3.37, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Bio Techne's use of debt, we should always consider it together with its cash and equity.

Bio Techne Total Assets Over Time

Bio Techne Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Bio Techne uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Bio Techne Debt Ratio

10.0

It feels like most of the Bio Techne's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Bio Techne's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Bio Techne, which in turn will lower the firm's financial flexibility.

Bio Techne Corporate Bonds Issued

Bio Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bio Techne prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Bio Techne. By using and applying Bio Stock analysis, traders can create a robust methodology for identifying Bio entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Bio Techne Corp stock analysis indicators help investors evaluate how Bio Techne stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bio Techne shares will generate the highest return on investment. By understating and applying Bio Techne stock analysis, traders can identify Bio Techne position entry and exit signals to maximize returns.

When running Bio Techne's price analysis, check to measure Bio Techne's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Techne is operating at the current time. Most of Bio Techne's value examination focuses on studying past and present price action to predict the probability of Bio Techne's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Techne's price. Additionally, you may evaluate how the addition of Bio Techne to your portfolios can decrease your overall portfolio volatility.